Article highlights promising preliminary results and path forward for FDA-approved stem cell treatment study
The Tisch Multiple Sclerosis Research Center of New York, the world’s largest independent research center focusing on MS, is proud to announce that its FDA-approved stem cell treatment study was featured in an article in BioSpace.
Preliminary analysis of the study results found that stem cell treatments substantially improved muscle strength and disability scores, particularly among patients with lower levels of disability. Interviewing Dr. Saud A. Sadiq, the Director and Chief Research Scientist of the Tisch MSRCNY, as well as Senior Research Scientist Dr. Violaine Harris, the article features the progress and key results of the stem cell treatment study, as well as the broader history and goals of the center.
“We are excited to share more about our stem cell treatment research, which is a key study in service of our center’s overarching goal of finding the cause of and the cure for MS,” said Dr. Sadiq. “Furthermore, the study has enormous potential not only for the treatment of MS patients, but also promising potential implications for those with other neurodegenerative diseases. We’re delighted to share our analysis with the broader public and scientific community, and look forward to sharing further updates on this groundbreaking research as it progresses.”
The full BioSpace article can be accessed here.
About the Tisch MS Research Center of New York
The mission of the Tisch Multiple Sclerosis Research Center of New York is to conduct groundbreaking medical research to ensure unparalleled care and positive outcomes for MS patients. Its integrated relationship with the International Multiple Sclerosis Management Practice (IMSMP) accelerates the pace at which research discoveries translate from lab bench to bedside. The Center aims to identify the cause of MS, understand disease mechanisms, optimize therapies, and repair the damage caused by MS while offering patients access to the best and most advanced treatments possible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005121/en/
Contacts
Kerry Close
kclose@groupgordon.com
